June 26, 2020: “Soleno Therapeutics announced the closing of its previously announced underwritten public offering of 34,848,484 shares of its common stock, including 4,545,454 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $1.65 per share.
The net proceeds of the offering were approximately $53.7 million, after deducting the underwriting discount and other offering expenses.
Guggenheim Securities, LLC acted as the sole book-running manager for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering, and Laidlaw & Company (UK) Ltd. acted as co-manager for the offering.
The offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-232068) previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”) on July 23, 2019, and a preliminary prospectus supplement filed with the SEC on June 23, 2020, and a final prospectus supplement filed with the SEC on June 25, 2020.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.”
http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-closing-575-million-public
